

Press Release

Lonza and Adva Biotechnology Ltd. Agree to Expand Availability and Use of Automated Bioreactors with License to Lonza's Patents

- Lonza and Adva have entered into a license agreement ensuring broad access to smart automation technology
 - With this agreement, Lonza and Adva have resolved their related patent litigation in the United States
-

Basel, Switzerland, 24 June 2022 – Effective May 15, 2022, Lonza and Adva Biotechnology Ltd. (“Adva”) have entered into a license agreement that will provide Adva access to core intellectual property enabling the expansion of automated bioreactors globally. Through the agreement, Lonza grants Adva a non-exclusive license to certain patents in its portfolio directed to smart automation and bioreactor control. Lonza and Adva have dismissed their ongoing litigation in the United States.

Previously, on January 21, 2022, in the United States District Court for the District of Maryland, Lonza obtained a preliminary injunction against Adva, preventing Adva from importing and offering their Adva X³[®] device in the United States pending resolution of the case. With this agreement, this litigation and the injunction are now dismissed.

Adam Bryan, Head of Personalized Medicine, Lonza, commented: “Lonza, as a leading technology supplier to cell and gene therapy developers, believes that smart automation is the path to address the challenges of scale facing the industry. By signing this agreement with Adva, both parties ensure that patients have clear access to technology that is needed to truly revolutionize cell therapy manufacturing. This agreement reflects the tremendous investment that Lonza has made in developing enabling technologies to enable a healthier world and we hope this agreement will allow Adva’s customers to continue developing and manufacturing life-changing therapies.”

Ohad Karnieli, Ph. D., CEO of Adva Biotechnology Ltd., added: “Adva Biotechnology’s vision is “*Valuing life, granting advanced therapies to patients*”. Therefore, Adva had developed a state-of-the-art smart advanced therapy manufacturing platform that can revolutionize the industry and enable more patients to be treated and lives to be saved. This agreement with Lonza reflects the common mission of enabling advanced therapies and allows Adva to further develop its robust solutions for the benefit of patients worldwide. Smart manufacturing platforms will revolutionize the way we treat cancer, and we are extremely excited to move forward with this mission. Concurrent to the license agreement, Adva is launching its ADVA X³[®] platform in the USA, which will grant patients access to life-saving therapies. Furthermore, this license will allow Adva to continue and develop more innovative solutions for the cell and gene therapies industry.”

About Lonza

Lonza is a preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 16,000 full-time employees, we comprise high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 5.4 billion with a CORE EBITDA of CHF 1.7 billion in Full-Year 2021. Find out more at www.lonza.com.

As a leading innovator in the pharmaceutical and biologics manufacturing industry, Lonza has many patents covering their innovative offerings. For more information on Lonza's patent portfolio, please visit www.lonza.com/ip.

Follow @Lonza on [LinkedIn](#)

Follow @LonzaGroup on [Twitter](#)

About Adva Biotechnology Ltd

Adva Biotechnology is an Israeli-based private innovative company that is focused on developing advanced therapies manufacturing platforms such as the automated AI-backed Adva X³® platform for autologous therapies. ADVA Biotechnology was founded in 2016 with the vision of "Valuing life, granting advanced therapies to patients". Adva had developed and launched the Adva X³® platform to enable decentralized and cost-effective autologous therapies such as CAR T, TCR, NK, TIL and more. By utilizing 14 different controlled environmental and metabolic parameters backed with machine learning and artificial intelligence, the ADVA X³® platform simplifies and facilitates cell manufacturing bringing the therapies closed to the patents and reducing the cost and logistics associated with the manufacturing of advanced therapies. Adva is developing additional solutions for advanced therapies such as exosomes and viral vectors. The company had successfully launched in Europe and Israel and will launch in the USA in the next couple of months with the aim of bringing these solutions to patients both in the US and around the world.

www.advabio.com

Follow @ADVA Biotechnology on LinkedIn

Adva Contact Details

Dror Armon

VP Commercial Operations

ADVA Biotechnology, Ltd.

Tel +972 77 880 4906

dror@advabio.com

Ofra Toledo,

VP of Business Development and Legal affairs

ADVA Biotechnology, Ltd.

Tel +972 77 880 4903

ofra@advabio.com

Lonza Contact Details

Victoria Morgan

Head of External Communications

Lonza Group Ltd

Tel +41 61 316 2283

victoria.morgan@lonza.com

Dirk Oehlers

Investor Relations

Lonza Group Ltd

Tel +41 61 316 8540

dirk.oehlers@lonza.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.